Precision Vaccine Development: Unraveling the Immunoinformatics Code Against Epstein-Barr Virus's T41 Glycoprotein 350/220

Epstein-Barr Virus (EBV) poses a substantial global health threat, with a 90% morbidity rate in adults worldwide. Linked to infectious mononucleosis, autoimmune diseases, and cancers, there is an imperative for effective preventive measures, given the absence of current vaccines or medications. This study employs a bioinformatics strategy to design an epitope vaccine targeting EBV. The primary target for immunity is the EBV glycoprotein 350/220 (gp350), which mediates attachment to B cells through complement receptor 2 (CR2/CD21). The selected protein, EBV glycoprotein 350/220 was chosen based on its role in pathogenicity. In the post-therapeutic approach, three-dimensional structure prediction, validation, and verification processes were conducted, followed by molecular docking studies to identify potential drug-binding sites and suitable therapeutic inhibitors for the target protein. The protein's ability to stimulate humoral and cell-mediated immunity was assessed, leading to the identification of a peptide segment ATNLFLLEL from positions 342 to 356 as the predominant T cell epitope. This epitope demonstrated compatibility with various HLA profiles, enhanced by its interaction with eight HLA-A and HLA-B alleles. Population coverage analysis revealed broad responsiveness across geographies, suggesting its potential as a widely applicable vaccine component. Its non-allergic classification further supports its potential efficacy for diverse individuals. Docking studies with HLA-B*3501 confirmed its significant affinity for MHC-I molecules, establishing it as a promising vaccination candidate. Additionally, a region from amino acid positions 253 to 310 was identified as containing potential B-cell epitopes, with the sequence "LGAGELALTMRSKKLP" showing promise due to its antigenic potential. This computational approach to epitope-based peptide vaccine design and target site prediction against EBV represents a pioneering advancement in EBV virus research, emphasizing the need for validation through in vitro and in vivo trials.